Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.57 |
| ▸ | PLTP | P55058 | 3/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490614 | 0.93 | NPC1 (0.51) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL2491014 | 0.92 | ADORA1 (0.55) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL2314988 | 0.90 | TRPV4 (0.54) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL2487506 | 0.88 | PLTP (0.52) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL12206433 | 0.86 | TRPV4 (0.46) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL2487253 | 0.85 | PLTP (0.50) | TRPV4PLTPRORCDGAT1ADORA1 | |
| SCHEMBL2485677 | 0.85 | PLTP (0.51) | PLTPRORCDGAT1ADORA1HPGD | |
| SCHEMBL1304252 | 0.85 | TRPV4 (0.66) | TRPV4PLTPADORA1MAPTADORA3 | |
| SCHEMBL2487360 | 0.85 | DGAT1 (0.63) | PLTPRORCDGAT1ADORA1HPGD | |
| SCHEMBL2487641 | 0.85 | DGAT1 (0.49) | PLTPRORCDGAT1ADORA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| CN-102119047-A | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | TRPV4 3122/4885PLTP 575/4885RORC 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.